Home › Peripheral Arterial Disease › NCT06409949

MitoQ Treatment of Claudication: Myofiber and Micro-vessel Pathology

Who can join

Ages 21 and older · All sexes

Inclusion Criteria:

1. a positive history of chronic claudication
2. exercise-limiting claudication established by history and direct observation during a screening walking test administered by the evaluating vascular surgeon
3. documented lower extremity arterial occlusive disease based on ankle/brachial index measurements and/or arterial imaging
4. stable blood pressure, lipid and diabetes regimens and risk factor control for 6 weeks.

Exclusion Criteria:

1. rest pain or tissue loss due to PAD (Fontaine stage III and IV)
2. acute lower extremity ischemic event
3. walking capacity significantly and primarily limited by conditions other than claudication including leg (joint/musculoskeletal, neurologic) and systemic (heart, lung disease) pathology.

About the study

In our research, we are delving into whether taking MitoQ for six months can improve the symptoms and function of people diagnosed with peripheral artery disease, especially those who suffer from leg pain while walking, known as intermittent claudication. We will be checking if MitoQ helps people with claudication walk better, be more active every day, feel better about their lives, and if it enhances the health of their leg muscles.

What is being tested

• Walking assessment (diagnostic test)
• QOL Survey (other)
• Ankle pressure at rest and after stress (diagnostic test)
• Muscle Oxygen (diagnostic test)
• Serum MitoQ Level (diagnostic test)
• Needle Biopsy (procedure)

Sponsor: University of Nebraska · Participants: 60 · Started: Jun 1, 2023

Contact the study team

• Holly DeSpiegelaere, BSN RN CCRC · Phone: 402-995-4171

Official record on ClinicalTrials.gov — NCT06409949

Locations in the U.S.

Conditions

• Peripheral Arterial Disease

From ClinicalTrials.gov, data retrieved Oct 2, 2026. Each study sets its own eligibility; the study team decides who can join.